209917-48-6

Basic information

• Product Name: N-tert-Butyl 4-Aminophenylsulfonamide
• Synonyms: N-tert-Butyl 4-Aminophenylsulfonamide;4-Amino-N-(1,1-dimethylethyl)benzenesulfonamide;N-t-Butyl 4-aMinophenylsulfonaMide;N-tert-Butyl-4-aminobenzenesulfonamide
• CAS NO: 209917-48-6
• Molecular Formula: C₁₀H₁₆N₂O₂S
• Molecular Weight: 228.32
• EINECS: 1312995-182-4
• Product Categories: Acids and Derivatives;Amines and Anilines
• Mol File: 209917-48-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 374.8 °C at 760 mmHg
• Flash Point: 180.5 °C
• Appearance: /
• Density: 1.189 g/cm³
• Vapor Pressure: 8.11E-06mmHg at 25°C
• Refractive Index: 1.552
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 12.95±0.50(Predicted)
• CAS DataBase Reference: N-tert-Butyl 4-Aminophenylsulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-Butyl 4-Aminophenylsulfonamide(209917-48-6)
• EPA Substance Registry System: N-tert-Butyl 4-Aminophenylsulfonamide(209917-48-6)

Safety Data

• Hazardous Substances Data: 209917-48-6(Hazardous Substances Data)

Usage

Uses

N-tert-Butyl-4-aminobenzenesulfonamide is an synthetic intermediate used in the synthesis of various pharmaceutical goods such as CK2 and PIM kinase inhibitors.

InChI:InChI=1/C10H16N2O2S/c1-10(2,3)12-15(13,14)9-6-4-8(11)5-7-9/h4-7,12H,11H2,1-3H3

Upstream product

• 103-84-4 Acetanilid 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 
• 49690-09-7 N-dimethylethyl-4-nitrobenzenesulfonamide 
• 294885-56-6 N-(4-(N-(tert-butyl)sulfamoyl)phenyl)acetamide 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 1028253-30-6 3-methyl-N-(4-sulfamoylphenyl)-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 1028253-28-2 N-(4-(tert-butylsulfamoyl)phenyl)-3-methyl-D-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 1028253-27-1 N-(4-(tert-butylsulfamoyl)phenyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 915006-33-6 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [4-tert-butylsulfamoyl-2-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-amide 
• 915006-34-7 4-amino-N-tert-butyl-3-(4,4-dimethyl-cyclohex-1-enyl)-benzenesulfonamide 
• 1028253-29-3 2-(4-(N-tert-butylsulfamoyl)phenylamino)-3,3-dimethylbutanoic acid 
• 608523-50-8 6-[4-(tert-Butylsulfamoyl)phenylazo]-pyridoxal-5-phosphate 
• 499777-85-4 1-(tert-butylaminosulfonylphenyl)-4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazole 
• 499777-84-3 1-(tert-butylaminosulfonylphenyl)-5-(3-fluoro-4-methoxyphenyl)imidazole 
• 265114-23-6 cimicoxib 
• 915006-43-8 4-amino-3-bromo-N-tert-butyl-benzenesulfonamide 

Relevant articles and documents

Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold

Recent reports have highlighted the dual bromodomains of TAF1 (TAF1(1,2)) as synergistic with BET inhibition in cellular cancer models, engendering interest in TAF/BET polypharmacology. Here, we examine structure activity relationships within the BI-2536 PLK1 kinase inhibitor scaffold, previously reported to bind BRD4. We examine binding by this ligand to TAF1(2) and apply structure guided design strategies to discriminate binding to both the PLK1 kinase and BRD4(1) bromodomain while retaining activity on TAF1(2). Through this effort we discover potent dual inhibitors of TAF1(2)/BRD4(1), as well as biased derivatives showing marked TAF1 selectivity. We resolve X-ray crystallographic data sets to examine the mechanisms of the observed TAF1 selectivity and to provide a resource for further development of this scaffold.

Effect of photodynamic antibacterial chemotherapy combined with antibiotics on Gram-positive and gram-negative bacteria

The well-known and rapidly growing phenomenon of bacterial resistance to antibiotics is caused by uncontrolled, excessive and inappropriate use of antibiotics. One of alternatives to antibiotics is Photodynamic Antibacterial Chemotherapy (PACT). In the present study, the effect of PACT using a photosensitizer Rose Bengal alone and in combination with antibiotics including methicillin and derivatives of sulfanilamide synthesized by us was tested against antibiotic-sensitive and antibiotic-resistant clinical isolates of Gram-positive S. aureus and Gram-negative P. aeruginosa. Antibiotic-sensitive and resistant strains of P. aeruginosa were eradicated by Rose Bengal under illumination and by sulfanilamide but were not inhibited by new sulfanilamide derivatives. No increase in sensitivity of P. aeruginosa cells to sulfanilamide was observed upon a combination of Rose Bengal and sulfanilamide under illumination. All tested S. aureus strains (MSSA and MRSA) were effectively inhibited by PACT. When treated with sub-MIC concentrations of Rose Bengal under illumination, the minimum inhibitory concentrations (MIC) of methicillin decreased significantly for MSSA and MRSA strains. In some cases, antibiotic sensitivity of resistant strains can be restored by combining antibiotics with PACT.

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.